Delving into discrepancies, a single-center experience with Accelerate Pheno for gram-negative bacteremia, a rapid phenotypic susceptibility testing method

深入探究差异,一项针对革兰氏阴性菌血症的快速表型药敏试验方法Accelerate Pheno的单中心经验

阅读:1

Abstract

OBJECTIVE: Discrepancies or inaccuracies between testing methods can create confusion or lead to clinical harm if antibiotics are inappropriately chosen. We report our clinical experience using the Accelerate Pheno™ followed by routine automated susceptibilities by the Vitek®2 for positive blood cultures with gram-negative rods. DESIGN: This was a retrospective review of positive gram-negative blood cultures, including comparison of susceptibility testing results and impact on clinical care. SETTING: Academic teaching hospital. PATIENTS PARTICIPANTS: All patients admitted to the hospital with gram-negative bacteremia from January 2020 to December 2022. METHODS: Microbiology was reviewed for discrepancies as defined by very major errors (VMEs), major errors (MEs), and minor errors (mEs). Clinical charts were reviewed for antibiotic therapy. RESULTS: Positive blood cultures with gram-negative rods were included (n = 262). Between these two methods, overall essential agreement was 93.7% (2162/2304) and categorical agreement 93.5% (2159/2306). There were 147 discrepancies noted, including 6 VMEs, 25 MEs, and 116 mEs accounting for 96 patients. Antibiotic choice was changed in 8 patients due to perceived suboptimal empiric therapy based on the rapid susceptibility results. CONCLUSIONS: The Accelerate Pheno tended to over-call resistance compared to the Vitek®2. Few patients (8) received the incorrect antibiotic based on the Pheno result. Stewardship programs may choose to optimize their rapid antibiotic susceptibility testing reporting to help minimize confusion and guide appropriate antibiotic selection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。